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Introduction: Optimal management of clinical stage IIIA-N2 non–
small-cell lung cancer (NSCLC) is controversial. This study examines 
whether neoadjuvant chemoradiation plus surgery improves survival 
rates when compared with other recommended treatment strategies.
Methods: Adult patients from the National Cancer Database, 
with clinical stage IIIA-N2 disease definitively treated between 
1998 and 2004 at American College of Surgeons Commission on 
Cancer accredited facilities, were included in the study. Treatment 
was defined as neoadjuvant chemoradiation plus either lobectomy 
(NeoCRT+L) or pneumonectomy (NeoCRT+P), lobectomy plus 
adjuvant therapy (L+AT), pneumonectomy plus adjuvant therapy 
(P+AT), and concurrent chemoradiation (CRT). Median follow-up 
and overall survival (OS) were defined from date of diagnosis to last 
contact. Five-year OS was estimated using Kaplan–Meier methods. 
Cox proportional hazard regression was used to estimate hazard 
ratios and 95% confidence intervals (CIs), adjusting for sociodemo-
graphic, clinical, and facility characteristics.
Results: Median follow-up was 11.8 months for 11,242 eligible 
patients. Five-year OS was 33.5%, 20.7%, 20.3%, 13.35%, and 
10.9% for NeoCRT+L, NeoCRT+P, L+AT, P+AT, and CRT, respec-
tively (p < 0.0001). On multivariable analysis, the estimated hazard 
ratio was 0.51 (CI: 0.45–0.58) for NeoCRT+L; 0.77 (0.63–0.95) for 
NeoCRT+P; 0.66 (0.59–0.75) for L+AT; 0.69 (0.54–0.88) for P+AT; 
and 1.0 (reference) for the CRT group. Comorbidity did not attenuate 
the relationship between treatment and survival.
Conclusion: This large study demonstrates that patients with 
clinical stage IIIA-N2 NSCLC, who underwent neoadjuvant 
chemoradiation followed by lobectomy, were associated with an 
improved survival.
Key Words: Lung cancer, Neoadjuvant chemoradiation.
(J Thorac Oncol. 2013;8: 915-922)
Treating clinical stage IIIA-N2 non–small-cell lung can-cer (NSCLC) is a significant challenge.1 The high rate 
of local failure seen in the population treated with chemora-
diation alone led investigators to examine whether neoadju-
vant chemoradiation (NeoCRT) plus curative-intent surgical 
resection could decrease locoregional recurrence rates and 
improve survival. The main concern regarding this approach 
is the potential for increased surgical morbidity and mortality. 
NeoCRT can cause worsening of inflammation, which may 
increase the complication rates associated with subsequent 
surgical resection.2
Several phase II studies initially suggested an over-
all survival (OS) benefit of 10% to 20% from NeoCRT and 
surgery, with most trials reporting a median survival of 15 
to 22 months.3–8 However, three recent phase III randomized 
studies, which completed accrual, failed to confirm a clear 
survival benefit of neoadjuvant therapy.9–11 Because of these 
results, the role of neoadjuvant chemoradiation followed by 
a lobectomy or pneumonectomy in stage IIIA-N2 NSCLC 
remains controversial.12
The purpose of this study was to examine whether 
neoadjuvant chemoradiation was associated with improved 
survival compared with other recommended treatment strat-
egies among patients with clinical stage IIIA-N2 NSCLC, 
using observational data from the National Cancer Database 
(NCDB), which allows for an analysis of a much larger cohort 
of patients from a variety of clinical practices than previously 
published studies.
PATIENTS AND METHODS
The NCDB is a hospital-based cancer registry that 
collects data from American College of Surgeons (ACoS) 
Commission on Cancer (CoC) accredited facilities and is 
jointly sponsored by the ACoS and the American Cancer 
Society. It includes data on approximately 70% of all 
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malignant cancers in the United States. The database contains 
information on patient demographics, primary tumor site, 
histology, stage at diagnosis, insurance status, first course of 
treatment, and OS.
Data and Study Population
Eligible patients had histologically confirmed first pri-
mary invasive NSCLC and received all or part of their first 
course of treatment at ACoS CoC accredited facilities.13 We 
restricted the analysis to patients aged 19 years and older, 
with pretreatment clinical stage IIIA-N2 (T1–T3) disease, 
treated between 1998 and 2004, to allow for a minimum of 5 
years of follow-up (n = 39,359). Patients were not required to 
have histologic confirmation of clinical N2 disease because 
this information was unavailable in the database. The treat-
ment categories were selected a priori according to a review 
of the literature. The five recommended treatment strate-
gies in this population, which were consistent with curative 
therapy, according to evidence-based guidelines released by 
various oncologic societies for positive clinical N2 nodal sta-
tus included neoadjuvant chemoradiation plus a lobectomy 
(NeoCRT+L), neoadjuvant chemoradiation plus a pneumo-
nectomy (NeoCRT+P), lobectomy plus adjuvant therapy 
(L+AT), pneumonectomy plus adjuvant therapy (P+AT), and 
concurrent chemoradiation (CRT) alone.14–18 Adjuvant therapy 
included chemotherapy alone, radiation alone, and chemora-
diation. Patients with missing demographic data (n = 126), 
missing treatment data (n = 7755), those who did not receive 
treatment (n = 4358), those who received chemotherapy or 
radiation therapy alone (n = 9431), or who received treatment 
that did not meet criteria established for the three categories 
as mentioned above, such as sequential chemotherapy and 
radiation, were excluded (n = 6447). All patients were retro-
spectively classified into each category, based on the actual 
treatment they received.
The ACoS CoC requires accredited programs to update 
vital status and other information in 5-year cycles; for exam-
ple, patients first diagnosed with cancer in 1998 (1998 incident 
cases) would be initially reported in 2000 and would have their 
vital status updated in 2005 (which would be the same year 
when the 2003 incident cases would be reported). After the 
initial 5-year follow-up, the vital status of the case and follow-
up time are updated on an annual basis. The NCDB does not 
have cause of death data. Therefore, for this study, overall fol-
low-up time was defined as the time from diagnosis to date of 
death from any cause, or the time from diagnosis to date of last 
contact for those who were alive at last contact. Patient risk 
factors that were part of the statistical analysis included histol-
ogy, T-stage (according to the 6th edition of the American Joint 
Committee on Cancer Stage), laterality, age at diagnosis, sex, 
insurance type, race/ethnicity, and geographic region.19 The 
variables and categorizations were based on previously pub-
lished data sets examining prognostic factors in lung cancer 
patients.20,21 Among patients who underwent surgery, the sur-
gical margin status of the pulmonary resection was recorded. 
From 2003, the NCDB began collecting data on comorbidi-
ties from the hospital face sheet. A modified version of the 
17-item Charlson–Deyo Index (eliminating solid tumors and 
leukemia) was computed to permit adjustment for comorbidi-
ties.22 The 15-item modified index measured conditions such 
as diabetes, myocardial infarction, and kidney failure.
Facility-level characteristics included the volume of 
patients who received care for NSCLC at an ACoS CoC facil-
ity during the study period and treatment facility type. Four 
types of treatment facilities were included in the classification 
scheme used by the CoC accreditation program, (1) commu-
nity cancer programs, (2) comprehensive community cancer 
programs, (3) teaching or research centers, and (4) National 
Cancer Institute–designated cancer centers. Community can-
cer centers treat at least 300 cancer patients a year and have 
a full range of services for cancer care. Comprehensive com-
munity cancer centers offer the same range of services as the 
community hospitals but treat at least 650 cancer patients 
annually. Teaching/research facilities are affiliated with medi-
cal schools, have residency programs, conduct ongoing cancer 
research, and have no minimum caseload requirement.
Statistical Analysis
Median follow-up was calculated among individuals 
with censored data.23 Estimates of OS, stratified by the treat-
ment received, were calculated using Kaplan–Meier survival 
estimates. The log-rank test was used to estimate whether there 
were differences in OS rate by treatment type. Differences in 
treatment type by patient, facility, and area-level characteris-
tics were estimated using χ2 tests. All statistical tests were two 
sided, and a 0.05 level of significance was used.
Multivariable Cox proportional hazards (PHs) regression 
models were used to assess the importance of treatment 
received as an independent predictor of OS. All statistically 
significant (at the 0.05 level) data on patient, facility, and area-
level variables from the aforementioned bivariate analysis were 
included in the multivariate Cox PH analysis. Hazard ratios 
(HRs) and corresponding 95% confidence intervals (CIs) 
were estimated in models adjusted for the aforementioned 
covariates of interest. A test for PHs in initial survival models 
revealed time interactions among several factors, including 
histopathology, sex, clinical T-stage, laterality, diagnosis year, 
and age at diagnosis. Because of the violation of PH for these 
variables, we controlled for these variables by stratification. 
Stratification allows for different stratum to have different 
baseline hazard functions and ultimately results in an HR 
being weighted over the different strata. This procedure allows 
for simultaneous calculation of HR for those variables that 
do not violate the PH assumption, but it does preclude the 
generation of HR estimates for variables that do violate the PH 
assumption.24,25 Furthermore, the treatment category violated 
the PH assumption within the first 4 months of follow-up. The 
Cox proportional hazards model relies on the hazards to be 
proportional, meaning that the effect of a given covariate does 
not change over time. The treatment category violated PH in 
the first 4 months of follow-up. To correct this, we performed 
multivariate analysis on patients who survived a minimum of 
4 months, after which the treatment variable did not violate 
the PH assumption (n = 10,058). Use of the 4-month cutoff 
in the multivariate analysis also reduced potential time biases 
from differences in the duration of therapy.26–28
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TABLE 1.  Patient, Facility and Area-Level Characteristics by Treatment Type among Clinical Stage IIIA-N2 Non–Small-Cell Lung 
Cancer Patients, National Cancer Database (NCDB) 1998–2004
Categories Total
Neoadjuvant  
Chemoradiotherapy + 
Lobectomy
Neoadjuvant  
Chemoradiotherapy + 
Pneumonectomy
Lobectomy 
+ Adjuvant 
Therapy
Pneumonectomy + 
Adjuvant  
Therapy
Definitive  
Concurrent  
Chemoradiotherapy p
N = 11242 n = 564 n = 188 n = 510 n = 123 n = 9857
% (4.94) (1.65) (4.46) (1.08) (86.28)
N (%) n (%) n (%) n (%) n (%) n (%)
Sex <0.0001
 Men 6654 (59.19) 313 (55.5) 123 (65.43) 256 (50.2) 90 (73.17) 5872 (59.57)
 Women 4588 (40.81) 251 (44.5) 65 (34.57) 254 (49.8) 33 (26.83) 3985 (40.43)
Race/ethnicity 0.0003
 Non-Hispanic, white 8647 (76.92) 470 (83.33) 140 (74.47) 403 (79.02) 88 (71.54) 7546 (76.55)
 Hispanic 161 (1.43) a a a a 142 (1.44)
 Black 1220 (10.85) 31 (5.5) 18 (9.57) 41 (8.04) 12 (9.76) 1118 (11.34)
 Other 145 (1.29) 10 (1.77) a 10 (1.96) a 120 (1.22)
 Missing 1069 (9.51) 49 (8.69) 24 (12.77) 48 (9.41) 17 (13.82) 931 (9.45)
Insurance status <0.0001
 Uninsured 311 (2.77) a a 13 (2.55) a 284 (2.88)
 Medicaid 540 (4.8) 22 (3.9) a 20 (3.92) a 484 (4.91)
 Younger medicare 623 (5.54) 27 (4.79) a 24 (4.71) a 562 (5.7)
 Older medicare 4921 (43.77) 153 (27.13) 42 (22.34) 211 (41.37) 29 (23.58) 4486 (45.51)
 Private 4288 (38.14) 330 (58.51) 121 (64.36) 217 (42.55) 71 (57.72) 3549 (36)
 Missing 559 (4.97) 25 (4.43) a 25 (4.9) a 492 (4.99)
Age, yr <0.0001
 19–59 3351 (29.81) 259 (45.92) 103 (54.79) 165 (32.35) 61 (49.59) 2763 (28.03)
 60–69 3951 (35.14) 217 (38.48) 69 (36.7) 176 (34.51) 42 (34.15) 3447 (34.97)
 70–79 3326 (29.59) 83 (14.72) 16 (8.51) 150 (29.41) 20 (16.26) 3057 (31.01)
 80+ 614 (5.46) a a 19 (3.73) a 590 (5.99)
Year of diagnosis year <0.0001
 1998 834 (7.42) 32 (5.67) 22 (11.7) 48 (9.41) 23 (18.7) 709 (7.19)
 1999 972 (8.65) 59 (10.46) 22 (11.7) 53 (10.39) 22 (17.89) 816 (8.28)
 2000 1405 (12.5) 81 (14.36) 28 (14.89) 67 (13.14) 21 (17.07) 1208 (12.26)
 2001 1787 (15.9) 86 (15.25) 19 (10.11) 70 (13.73) 13 (10.57) 1599 (16.22)
 2002 1792 (15.94) 73 (12.94) 27 (14.36) 63 (12.35) 11 (8.94) 1618 (16.41)
 2003 2290 (20.37) 123 (21.81) 33 (17.55) 100 (19.61) 17 (13.82) 2017 (20.46)
 2004 2162 (19.23) 110 (19.5) 37 (19.68) 109 (21.37) 110 (19.5) 1890 (19.17)
Histology <0.0001
 Adenocarcinoma 3687 (32.8) 272 (48.23) 54 (28.72) 318 (62.35) 53 (43.09) 2990 (30.33)
 Large-cell 918 (8.17) 47 (8.33) a 37 (7.25) 10 (8.13) 816 (8.28)
 Squamous cell 2298 (20.44) 92 (16.31) 31 (16.49) 35 (6.86) a 2133 (21.64)
 NSCLC NOS 4339 (38.6) 153 (27.13) 95 (50.53) 120 (23.53) 53 (43.09) 3918 (39.75)
Clinical T-stage <0.0001
 T1 1923 (17.11) 134 (23.76) 20 (10.64) 157 (30.78) 15 (12.2) 1597 (16.2)
 T2 5968 (53.09) 305 (54.08) 100 (53.19) 306 (60) 81 (65.85) 5176 (52.51)
 T3 3351 (29.81) 125 (22.16) 68 (36.17) 47 (9.22) 27 (21.95) 3084 (31.29)
Laterality <0.0001
 Right 6661 (59.25) 387 (68.62) 90 (47.87) 275 (53.92) 54 (43.9) 5855 (59.4)
 Left 3677 (32.71) 171 (30.32) 80 (42.55) 232 (45.49) 61 (49.59) 3133 (31.78)
 Bilateral a a a a a a
 Unknown 897 (7.98) 6 (1.06) 18 (9.57) 3 (0.59) 8 (6.5) 862 (8.75)
Facility type <0.0001
 CCP 1803 (16.04) 58 (10.28) 16 (8.51) 57 (11.18) 12 (9.76) 1660 (16.84)
(Continued )
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As mentioned above, the NCDB began collecting comor-
bidity data in 2003. A separate multivariable analysis was per-
formed using data from 2003 to 2004 (n = 4025), in which 
the Charlson-Deyo comorbidity score was also included, as a 
covariate of interest, to determine whether comorbidity attenu-
ated the relationship between survival and treatment. Because 
of the very small number of patients in some treatment cat-
egories with two or more comorbidities coded, we restricted 
the comorbidity analysis to two groups, 0, and 1 or more. Data 
were analyzed using SAS software (version 9.2; SAS Institute 
Incorporated, Cary, NC).
RESULTS
A total of 11,242 patients met the inclusion criteria. The 
overall median follow-up time for all patients was 11.8 months 
(range, <1 month to 60 months) and 60 months among those 
who were alive at last contact (1279 patients). The median 
follow-up of patients who lived a minimum of 4 months (n = 
10,058), which was the cohort analyzed in the multivariable 
analysis, was 13.5 months. In patients who lived less than 4 
months, the median time to treatment was 16 days and median 
OS was approximately 3 months and the majority received 
chemoradiation (96%). Of the entire cohort, 4% of patients 
were lost to follow-up (alive at last contact but followed up for 
<5 years). The median age at diagnosis was 65 years. Patient 
characteristics are shown in Table 1. Male patients comprised 
59% of the cohort. The majority of patients had either squa-
mous cell carcinoma or adenocarcinoma (20% and 33%, 
respectively). Among patients who underwent surgical resec-
tion, the percentage of patients with positive surgical margins 
was 9.75% and did not vary significantly among the surgi-
cal treatment groups (p = 0.13). The 90-day mortality among 
patients who underwent surgical resection was as follows: 
1.6% in the NeoCRT+P group, 0% in the NeoCRT+L group, 
2.46% in the P+AT group, and 1.97% in the L+AT group. 
Approximately 70% of the patients in the cohort were older 
than 59 years of age. By type of treatment, 4.9% of the cohort 
underwent NeoCRT+L, 1.7% underwent NeoCRT+P, 4.5% 
underwent L+AT, 1.1% underwent P+AT, and 86.3% under-
went CRT. Among the patients who underwent L+AT or P+AT, 
similar percentages of patients received adjuvant chemother-
apy and radiation therapy (43.4% versus 46.3%, respectively), 
adjuvant radiation alone (31.1% versus 32.5%), and adjuvant 
chemotherapy alone (25.5% versus 21.0%). A high propor-
tion of patients treated with NeoCRT+L were white, younger 
(<70 years), and had larger tumors (T2). Among the cohort 
who underwent neoadjuvant therapy followed by surgery, 23% 
had a complete pathologic response. In the 2003–2004 cohort, 
comorbidity did not vary by treatment type (p = 0.10).
The 5-year OS was 33.5%, 20.8%, 20.3%, 13.4%, 
and 10.9% for the NeoCRT+L, NeoCRT+P, L+AT, P+AT, 
and CRT groups, respectively (p < 0.0001) (Fig. 1). In the 
cohort that had a complete pathologic response after neoadju-
vant chemoradiation the 5-year OS was 40%. For the 10,058 
patients, who lived 4 months or longer, age, sex, laterality, 
T-stage, histology, and diagnosis year were controlled for at 
TABLE 1.  (Continued )
Categories Total
Neoadjuvant  
Chemoradiotherapy + 
Lobectomy
Neoadjuvant  
Chemoradiotherapy + 
Pneumonectomy
Lobectomy 
+ Adjuvant 
Therapy
Pneumonectomy + 
Adjuvant  
Therapy
Definitive  
Concurrent  
Chemoradiotherapy p
 Comprehensive CCP 6251 (55.6) 262 (46.45) 89 (47.34) 237 (46.47) 58 (47.15) 5605 (56.86)
 Teaching/research 2432 (21.63) 165 (29.26) 61 (32.45) 139 (27.25) 32 (26.02) 2035 (20.65)
 NCI 590 (5.25) 68 (12.06) 19 (10.11) 73 (14.31) 17 (13.82) 413 (4.19)
 Missing 166 (1.48) 11 (1.95) a a a 144 (1.46)
Facility volume 0.17
 High 8446 (75.13) 445 (78.9) 151 (80.32) 390 (76.47) 97 (78.86) 7363 (74.7)
 Medium 2448 (21.78) 107 (18.97) 35 (18.62) 104 (20.39) 22 (17.89) 2180 (22.12)
 Low 348 (3.1) 12 (2.13) a 16 (3.14) a 314 (3.19)
Surgical margin status 0.13b
 Negative margins 1150 (83.03) 476 (84.4) 165 (87.77) 414 (81.18) 95 (77.24) N/A
 Positive margins 135 (9.75) 45 (7.98) 11 (5.85) 63 (12.35) 16 (13.01) N/A
 Margins not 
evaluable
14 (1.01) a a a a N/A
 Missing 86 (6.21) 36 (6.38) a 30 (5.88) a N/A
Comorbidities (%)c 0.10
  None 69.99% 73.39% 75.71% 64.59% 57.58% 70.08%
  ≥1 30.01% 26.61% 24.29% 35.41% 42.42% 29.92%
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) <0.0001
Age at diagnosis, yr 64.7 (10.11) 60.2 (9.15) 57.4 (9.45) 64 (10.07) 59.4 (9.96) 65.2 (10.04)
CCP, community cancer program; N/A, patients did not undergo surgery, so margin status is unobtainable; NCDB, National Cancer Database; NCI, National Cancer Institute 
Designated Facility.
a Data cell has <10 patients and is not shown to ensure patient confidentiality, per NCDB Data Use Agreement. 
b p value is among surgical patients only. 
c Percentages calculated are among the 2003–2004 cohort.
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the strata level in multivariate Cox models, as discussed pre-
viously. Furthermore, in this cohort there were no significant 
differences in the patient, facility, and area-level characteris-
tics compared with our initial cohort, as shown in Table 1. The 
estimated HR was 0.51 (95% CI: 0.45–0.58) for NeoCRT+L; 
0.77 (95% CI: 0.63–0.95) for NeoCRT+P; 0.66 (95% CI: 
0.59–0.75) for L+AT; 0.69 (95% CI: 0.54–0.88) for P+AT; 
and 1.0 for the CRT group (reference) (Table 2).
To examine the impact of comorbidities, the adjusted 
PH analyses were rerun, restricting the cohort to only 
those patients diagnosed from 2003 to 2004. Despite the 
existence of a significant association between comorbidity 
and survival (HR: 1.16; 95% CI: 1.06–1.26), the relationship 
between treatment and survival was unaltered. Adjusting for 
comorbidities in the 2003–2004 cohort, the estimated HR 
was 0.41 (95% CI: 0.33–0.50) for NeoCRT+L, 0.73 (95% 
CI: 0.52–1.02) for NeoCRT+P, 0.49 (95% CI: 0.40–0.60) 
for L+AT; 0.59 (95% CI: 0.38–0.93) for P+AT; and 1.0 for 
the CRT group (reference) (Table 3). We also ran a separate 
model, restricted to the same 2 years (2003–2004), but 
excluding comorbidity, and found similar HR and 95% CI for 
each treatment group (Table 3).
DISCUSSION
This large national hospital-based study examined the 
outcomes of patients with pretreatment clinical stage IIIA-N2 
NSCLC. Representing one of the largest cohorts examined 
to date, this observational study revealed that patients who 
underwent NeoCRT+L had a 49% reduced likelihood of 
death compared with those who underwent CRT after adjust-
ing for other important clinical, sociodemographic, and 
facility factors.
Neoadjuvant therapy in stage IIIA(N2) NSCLC was 
introduced in an effort to improve the poor survival rates seen 
historically in this cohort.29,30 The recently published phase III 
study, Intergroup 0139, randomized 396 patients with stage 
IIIA-N2 disease to either neoadjuvant chemoradiation plus 
surgical resection and consolidative chemotherapy, or concur-
rent chemoradiotherapy alone. The median OS rate of 27% 
in the neoadjuvant group versus 20% in the chemoradiation-
alone group did not differ significantly (odds ratio 0.63;95% 
CI: 0.36–1.10). However, a subgroup analysis revealed a sta-
tistically significant 5-year survival advantage for patients 
who received neoadjuvant chemoradiotherapy plus lobectomy 
compared with those who underwent chemoradiation alone 
(36% and 18%, respectively; p = 0.002).9
The delivery of neoadjuvant chemoradiation is complex 
and requires high-level multidisciplinary care and coordina-
tion.31 Thus, it was encouraging to note that our nationwide 
observational study involving patients treated in varying 
clinical settings, outside the context of a clinical study, had a 
5-year OS rate of 34% for the NeoCRT + L group, which is 
comparable to the 5-year OS rate of 36% seen in the NeoCRT 
+ L subset of the Intergroup 1039 study. This analysis also 
revealed that patients who had a complete pathologic nodal 
response had a 5-year survival of 40% and was in almost exact 
concordance with the findings of the intergroup 1039 study, 
which revealed a 5-year OS of 42% in patients with a com-
plete pathologic nodal response.
The current study was primarily limited by information 
that was unavailable in the NCDB database, including types 
of chemotherapy administered, pretreatment pathologic proof 
of clinical N2 disease, extent of mediastinal nodal involve-
ment (bulky versus nonbulky), number of mediastinal nodal 
stations involved, extent of disease, use of positron emission 
FIGURE 1.  Five-year overall survival 
among clinical stage IIIA-N2 NSCLC patients,  
National Cancer Database, 1998–2004, 
p < 0.0001. NSCLC, non–small-cell lung 
cancer.
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tomography scans, performance status, total radiotherapy 
dosage, overall treatment time, fractionation size, and radio-
therapy treatment technique. Furthermore, clinical stage IIIA 
(N2) NSCLC is a heterogeneous entity because of the extent 
of nodal involvement. Patients who present with bulky medi-
astinal adenopathy are considered inoperable and are more 
likely to undergo chemoradiation, which partially explains the 
worse survival seen in this cohort.32 The survival of patients 
who underwent chemoradation alone was 10.9% versus 20% in 
the Intergroup 0139 study. This difference is likely because the 
majority of patients in this study who underwent chemoradia-
tion had inoperable disease, which is associated with a worse 
prognosis, whereas all patients in the Intergroup study had 
operable disease. This pretreatment bias was at least  partially 
mitigated because we included a comparison group of patients 
that underwent lobectomy and adjuvant therapy. Such patients 
would have had an excellent performance status and nonbulky 
N2 disease because they were able to tolerate an upfront surgi-
cal procedure. Therefore, because of these pretreatment char-
acteristics we would have expected the L+AT group to have an 
improved survival compared with the other treatment groups. 
However, the multivariate analysis revealed the opposite, that 
the NeoCRT+L group had an improved survival (HR: 0.51; 
CI: 0.45–0.58) compared with the L+AT group (HR: 0.66; CI: 
0.59–0.75), lending further evidence to the fact that the dif-
ferences in survival reflect the differences caused by the treat-
ment. Furthermore, the rates of positive margins did not differ 
significantly between the surgical groups. Also, the cohort of 
patients receiving neoadjuvant therapy was small compared 
with the overall cohort examined, however, this finding is con-
sistent with other studies that have examined the receipt of 
neoadjuvant therapy in patients having stage III NSCLC.33,34
To account for differences in comorbidities between 
patients which may have explained the difference in OS among 
treatments, we adjusted for comorbidities among patients 
treated from 2003–2004, the period when the NCDB began 
collecting these data. Though comorbidity was significantly 
associated with survival, it did not attenuate the relationship 
between treatment and survival. Despite this, we acknowledge 
that this study has the inherent flaws of being a retrospec-
tive analysis, and is limited mainly by pretreatment selection 
biases, which include patients with better prognostic factors 
and improved performance status and who may have been 
more likely to have undergone neoadjuvant chemoradiation 
followed by surgery. Furthermore, a selection bias is intro-
duced because this analysis only examined the treatment as 
received, and it was impossible to ascertain how many patients 
were initially recommended to undergo neoadjuvant chemora-
diation followed by surgery but were unable to complete the 
treatment because of progression or treatment-related toxic-
ity. Another limitation is that variables that violated the PH 
assumption were used as stratification variables, which does 
not allow for assessing the impact of these variables on OS. 
When examining treatment so as to not violate the PH model, 
we had to exclude deaths within the first 4 months, which may 
also create a bias toward certain treatment categories. Also, 
the Charleson–Deyo comorbidity index does not provide as 
accurate an identification or severity of comorbid illness com-
pared with clinical databases.35 Thus, because these results 
come from an observational study, they should be considered 
as hypothesis-generating and could be considered for confir-
mation in future prospective studies.
The optimal management of stage IIIA(N2) NSCLC 
is not well defined and depends on a variety of factors.36 
Appropriate candidates for neoadjuvant chemoradiation fol-
lowed by surgery include those with T1–T3 disease and ipsi-
lateral positive mediastinal lymph nodes (maximum diameter 
<3 cm). Furthermore, they should have resectable disease as 
determined by a thoracic surgeon and have adequate pulmo-
nary function.
TABLE 2.  Multivariate Cox Proportional Hazard Models 
Predicting 5-year Overall Survival among Clinical Stage 
IIIA-N2 NSCLC Patients, NCDB 1998–2004 (n = 10,058)
5-Year Survivala,b
Parameter HR 95% CI
Treatment
 Definitive chemoradiation 1.00
Neoadjuvant chemoradiotherapy + 
lobectomy
0.51 (0.45–0.58)
Neoadjuvant chemoradiotherapy + 
pneumonectomy
0.77 (0.63–0.95)
 Lobectomy + adjuvant therapy 0.66 (0.59–0.75)
 Pneumonectomy + adjuvant therapy 0.69 (0.54–0.88)
Insurance status
 Private 1.00
 Uninsured 1.1 (0.93–1.30)
 Medicaid 1.2 (1.05–1.36)
 Younger Medicare 1.09 (0.97–1.23)
 Older Medicare 1.06 (0.98–1.13)
 Missing 1.4 (1.23–1.59)
Race/ethnicity
 Non-Hispanic white 1.00
 Hispanic 0.77 (0.62–0.96)
 Black 0.87 (0.79–0.95)
 Other 0.98 (0.78–1.22)
 Missing 1.03 (0.95–1.12)
Facility type
 Teaching/research 1.00
 CCP 1.04 (0.94–1.15)
 Comprehensive CCP 1.04 (0.97–1.11)
 NCI 0.95 (0.84–1.07)
 Missing 1.16 (0.92–1.47)
Facility volume
 High 1.00
 Medium 1.04 (0.96–1.12)
 Low 1.04 (0.87–1.23)
CCP, community cancer program; CI, confidence intervals; HR, hazard ratio; NCI, 
National Cancer Institute Designated Facility; NCDB, National Cancer Database; 
NSCLC, non–small-cell lung cancer.
a Models adjusted for age, sex, clinical T-stage, laterality, histology, and diagnosis 
year at the strata level. 
b Five-year survival starts at 121 days because of a violation in proportional hazards 
by treatment within the first 120 days of diagnosis.
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This study of hospital-based data has important clini-
cal significance because it is one of the largest observational 
studies to examine this issue, and suggests that neoadjuvant 
chemoradiation plus lobectomy may be appropriate in care-
fully selected individuals, and associated with a similar sur-
vival to that seen in the Intergroup 0139 study. This study also 
highlights the importance of patients with locally advanced 
lung cancer to be initially evaluated in a multidisciplinary 
setting with a thoracic surgeon, medical oncologist, and 
radiation oncologist, to determine the most appropriate initial 
treatment strategy.
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